ARTIS Ventures, a financial services firm, led a $16m Series A round in Affect Therapeutics, a company that uses mobile technology to revolutionize stimulant addiction recovery, with participation from AlleyCorp, LifeArc Ventures, Samsung Next, and What If Ventures. “Drug overdose deaths have reached record levels in the US, with no signs of abating, and yet the standard of care for substance use disorders is largely based on decades-old approaches with generally poor patient outcomes. By thoughtfully innovating with sound research, data, and well-proven engagement techniques, we can change all of that. We are relentless in developing innovative, evidence-based solutions that we deliver with extraordinary care and empathy to help millions of patients struggling with addiction," Kristin Muhlner, Affect Therapeutics Co-Founder and CEO.